So basically to sum it all up. Similar companies with the IPF drugs in 2014 were bought out for $8.3 billion, and one for $444 million that hasn't even started phase 1 trials (which we have already done). We are also working with Vodis Innovative Pharmaceuticals to develop therapies based on extracts from cannabis plants. The company also plans to uplist to a major US exchange soon, and we have a very low SS. Yup true GEM at these levels!
Market Data 
Markets 
AI
